Tandem Diabetes Care Sets 2026 Sales Outlook at $1.065 Billion to $1.085 Billion
Photo: TokenPost
Tandem Diabetes Care management expects worldwide sales of $1.065 billion to $1.085 billion in 2026, while CEO John Sheridan is preparing to retire at the end of 2026. For 2026, Tandem projects an adjusted EBITDA margin of 5% to 6%, alongside a 56% to 57% gross margin. Management described mid- to high-single-digit revenue growth in 2027 as a fair starting point. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.
Source: TokenPost
